{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:43:06Z","timestamp":1791265386671,"version":"4.1.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.clindermatol.2007.11.006","type":"journal-article","created":{"date-parts":[[2008,8,27]],"date-time":"2008-08-27T09:02:09Z","timestamp":1219827729000},"page":"438-447","source":"Crossref","is-referenced-by-count":79,"title":["Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine"],"prefix":"10.1016","volume":"26","author":[{"given":"Richard B.","family":"Warren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2007.11.006_bib1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remission of acute leukaemia in children produced by the folic acid antagonist 4 aminopteroylglutamic acid (aminopterin)","volume":"238","author":"Farber","year":"1948","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00000441-195102000-00009","article-title":"Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis","volume":"221","author":"Gubner","year":"1951","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archderm.1958.01560080060010","article-title":"Treatment of psoriasis with folic acid antagonists","volume":"78","author":"Edmundson","year":"1958","journal-title":"AMA Arch Derm"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib4","series-title":"Distribution of the reduced folate carrier (RFC) versus the high affinity membrane folate binding protein (mFBP) in human tumours and tissues","first-page":"307","author":"Matherly","year":"1994"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/0006-2952(93)90278-5","article-title":"Retentiveness of methotrexate polyglutamates in cultured L1210 cells. Evidence against a role for mediated plasma membrane transport outward","volume":"45","author":"Schlemmer","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib6","series-title":"Pteroylpolyglutamates: biosynthesis, degradation, and function","first-page":"135","author":"McGuire","year":"1984"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib7","series-title":"Cancer chemotherapy and biotherapy","first-page":"109","author":"Chu","year":"1996"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0049-0172(98)80049-8","article-title":"Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity","volume":"27","author":"van Ede","year":"1998","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib9","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/0006-2952(79)90039-X","article-title":"Human thymidylate synthetase\u2014III. Effects of methotrexate and folate analogs","volume":"28","author":"Szeto","year":"1979","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI112088","article-title":"Polyglutamation of methotrexate. Is methotrexate a prodrug?","volume":"76","author":"Chabner","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/ar419","article-title":"Molecular action of methotrexate in inflammatory diseases","volume":"4","author":"Chan","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib12","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1172\/JCI116884","article-title":"The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation","volume":"92","author":"Cronstein","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/bj2360193","article-title":"Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5\u2032-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide","volume":"236","author":"Baggott","year":"1986","journal-title":"Biochem J"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib14","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1073\/pnas.82.15.4881","article-title":"Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates","volume":"82","author":"Allegra","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib15","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.4049\/jimmunol.148.7.2201","article-title":"Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors","volume":"148","author":"Cronstein","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780350403","article-title":"Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate","volume":"35","author":"Sperling","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1172\/JCI2676","article-title":"Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells","volume":"102","author":"Genestier","year":"1998","journal-title":"J Clin Invest"},{"issue":"Pt 4","key":"10.1016\/j.clindermatol.2007.11.006_bib18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1242\/jcs.112.4.491","article-title":"Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation","volume":"112","author":"Mirabet","year":"1999","journal-title":"J Cell Sci"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clim.2004.09.001","article-title":"The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules","volume":"114","author":"Johnston","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.103.1.33","article-title":"Methotrexate for psoriasis. A new therapeutic schedule","volume":"103","author":"Weinstein","year":"1971","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1001\/archderm.104.3.236","article-title":"Methotrexate. Mechanism of action on DNA synthesis in psoriasis","volume":"104","author":"Weinstein","year":"1971","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib22","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.1964.03070100037007","article-title":"Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients","volume":"189","author":"Black","year":"1964","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000252574","article-title":"Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy","volume":"140","author":"Nyfors","year":"1970","journal-title":"Dermatologica"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib24","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0733-8635(18)30050-0","article-title":"Methotrexate and other chemotherapeutic agents used to treat psoriasis","volume":"13","author":"Jeffes","year":"1995","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib25","first-page":"623","article-title":"Methotrexate maintenance following Ingram therapy in \u2018difficult\u2019 psoriasis","volume":"106","author":"Van de Kerkhof","year":"1982","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib26","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2230.1992.tb02161.x","article-title":"The efficacy of methotrexate in psoriasis\u2014a review of 40 cases","volume":"17","author":"Collins","year":"1992","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib28","series-title":"Methotrexate: the conservative treatment for psoriasis","first-page":"235","author":"Baker","year":"1976"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2340\/0001555567270273","article-title":"Methotrexate treatment of psoriatic arthritis","volume":"67","author":"Zachariae","year":"1987","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib30","first-page":"208","article-title":"Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics","volume":"25","author":"Nyfors","year":"1978","journal-title":"Dan Med Bull"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/bmj.298.6676.801","article-title":"Methotrexate dosage in patients aged over 50 with psoriasis","volume":"298","author":"Fairris","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib32","first-page":"111","article-title":"Some hazards of methotrexate treatment of psoriasis","volume":"56","author":"Baker","year":"1970","journal-title":"Trans St Johns Hosp Dermatol Soc"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0190-9622(82)70005-2","article-title":"Combined methotrexate-PUVA therapy in the treatment of psoriasis","volume":"6","author":"Morison","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0190-9622(82)70157-4","article-title":"Combined methotrexate-ultraviolet B therapy in the treatment of psoriasis","volume":"7","author":"Paul","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archderm.118.3.177","article-title":"Methotrexate and ultraviolet radiation","volume":"118","author":"Armstrong","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib36","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archderm.118.9.660","article-title":"Methotrexate and etretinate as concurrent therapies in severe psoriasis","volume":"118","author":"Vanderveen","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(83)92606-5","article-title":"Synergistic carcinogenic potential of methotrexate and PUVA in psoriasis","volume":"1","author":"Fitzsimons","year":"1983","journal-title":"Lancet"},{"issue":"Suppl 49","key":"10.1016\/j.clindermatol.2007.11.006_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2133.1996.tb15661.x","article-title":"Oral retinoids\u2014efficacy and toxicity in psoriasis","volume":"135","author":"Gollnick","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib39","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/archderm.117.12.760","article-title":"Treatment of generalized pustular psoriasis with methotrexate and colchicine","volume":"117","author":"Horiguchi","year":"1981","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1365-2133.1999.02976.x","article-title":"Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis","volume":"141","author":"Clark","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2230.2006.02153.x","article-title":"Methotrexate and cyclosporine combination for the treatment of severe psoriasis","volume":"31","author":"Aydin","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib42","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1365-2133.2006.07289.x","article-title":"Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial","volume":"154","author":"Salim","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib43","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jaad.2005.06.036","article-title":"Folate supplementation during methotrexate therapy for patients with psoriasis","volume":"53","author":"Strober","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0190-9622(88)80237-8","article-title":"Methotrexate in psoriasis: revised guidelines","volume":"19","author":"Roenigk","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-4362.1988.tb02342.x","article-title":"Erosion of psoriatic plaques after chronic methotrexate administration","volume":"27","author":"Kaplan","year":"1988","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2133.1970.tb02194.x","article-title":"Intermittent high dose oral methotrexate therapy in psoriasis","volume":"82","author":"Baker","year":"1970","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib47","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2133.1971.tb02548.x","article-title":"Psoriasis, methotrexate and tuberculosis","volume":"84","author":"Smith","year":"1971","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib48","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Methotrexate in psoriasis: consensus conference","volume":"38","author":"Roenigk","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib49","first-page":"241","article-title":"Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics","volume":"69","author":"Zachariae","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib50","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2133.1996.tb03827.x","article-title":"Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients","volume":"135","author":"Boffa","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2133.2001.03959.x","article-title":"The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up","volume":"144","author":"Zachariae","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib52","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/archderm.132.2.184","article-title":"Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis","volume":"132","author":"Zonneveld","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/archderm.116.2.215","article-title":"Psoriasis, methotrexate, and oligospermia","volume":"116","author":"Sussman","year":"1980","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib54","first-page":"274","article-title":"Development of metastatic skin cancer during methotrexate therapy for psoriasis","volume":"69","author":"Jensen","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib55","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C","article-title":"The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study","volume":"73","author":"Stern","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib56","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2133.2005.06880.x","article-title":"The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis","volume":"153","author":"Warren","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib57","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2133.1982.tb00410.x","article-title":"A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population","volume":"107","author":"King","year":"1982","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib58","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1529-8019.2006.00083.x","article-title":"Treatment of cutaneous T-cell lymphoma with retinoids","volume":"9","author":"Zhang","year":"2006","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib59","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0190-9622(98)70594-8","article-title":"Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis","volume":"38","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib60","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0190-9622(98)70441-4","article-title":"Pharmacokinetics of acitretin and etretinate","volume":"39","author":"Wiegand","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib61","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/1523-1747.ep12472293","article-title":"Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol","volume":"100","author":"Larsen","year":"1993","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.clindermatol.2007.11.006_bib62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000248849","article-title":"Human skin retinoid-binding proteins and therapy with synthetic retinoids: a still unexplained link","volume":"175","author":"Saurat","year":"1987","journal-title":"Dermatologica"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib63","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/332850a0","article-title":"Identification of a second human retinoic acid receptor","volume":"332","author":"Brand","year":"1988","journal-title":"Nature"},{"issue":"Suppl 49","key":"10.1016\/j.clindermatol.2007.11.006_bib64","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2133.1996.tb15662.x","article-title":"Tazarotene\u2014first of a new generation of receptor-selective retinoids","volume":"135","author":"Chandraratna","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib65","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0014-4827(88)90396-5","article-title":"Specificity in the synergism between retinoic acid and EGF on the growth of adult human skin fibroblasts","volume":"178","author":"Harper","year":"1988","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib66","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1084\/jem.180.3.1141","article-title":"Overexpression of vascular permeability factor\/vascular endothelial growth factor and its receptors in psoriasis","volume":"180","author":"Detmar","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib67","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1074\/jbc.275.1.642","article-title":"Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids","volume":"275","author":"Diaz","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib68","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/1523-1747.ep12284027","article-title":"Synthetic retinoids inhibit the antigen presenting properties of epidermal cells in vitro","volume":"93","author":"Dupuy","year":"1989","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-4362.1984.tb05670.x","article-title":"Impaired motility and random migration of vital polymorphonuclears in vitro after therapy with oral aromatic retinoid in psoriasis","volume":"23","author":"Bauer","year":"1984","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib70","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0190-9622(89)70236-X","article-title":"A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis","volume":"21","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib71","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0190-9622(88)70163-2","article-title":"Systemic retinoid therapy for psoriasis","volume":"19","author":"Lowe","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib72","first-page":"104","article-title":"Acitretin treatment of severe psoriasis","volume":"146","author":"Torok","year":"1989","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib73","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2133.1987.tb04140.x","article-title":"Treatment of severe psoriasis with etretin (RO 10-1670)","volume":"117","author":"Lassus","year":"1987","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib74","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000248701","article-title":"Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies","volume":"176","author":"Geiger","year":"1988","journal-title":"Dermatologica"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib75","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0190-9622(88)70086-9","article-title":"Acitretin improves psoriasis in a dose-dependent fashion","volume":"18","author":"Goldfarb","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib76","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1529-8019.2006.00082.x","article-title":"Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology","volume":"9","author":"Van de Kerkhof","year":"2006","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib77","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1067\/mjd.2001.116347","article-title":"Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis","volume":"45","author":"Lebwohl","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib78","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2133.1998.02030.x","article-title":"The effect of addition of calcipotriol ointment (50 micrograms\/g) to acitretin therapy in psoriasis","volume":"138","author":"Van de Kerkhof","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib79","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0733-8635(03)00126-8","article-title":"Retinoid therapy for psoriasis","volume":"22","author":"Yamauchi","year":"2004","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib80","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0190-9622(99)70360-9","article-title":"Acitretin: optimal dosing strategies","volume":"41","author":"Ling","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib81","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(88)70198-X","article-title":"Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study","volume":"19","author":"Gollnick","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4400","article-title":"A systematic review of treatments for severe psoriasis","volume":"4","author":"Griffiths","year":"2000","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib83","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0190-9622(91)70253-X","article-title":"Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study","volume":"25","author":"Tanew","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib84","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000248567","article-title":"Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis","volume":"177","author":"Saurat","year":"1988","journal-title":"Dermatologica"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib85","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archderm.126.4.482","article-title":"Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis","volume":"126","author":"Ruzicka","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib86","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0190-9622(91)70089-K","article-title":"Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone","volume":"24","author":"Lowe","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib87","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1200\/JCO.1995.13.8.1933","article-title":"Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study","volume":"13","author":"Bavinck","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib88","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1172\/JCI2153","article-title":"Retinoic acid inhibits induction of c-Jun protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo","volume":"101","author":"Fisher","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib89","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJM198510033131401","article-title":"Retinoic acid embryopathy","volume":"313","author":"Lammer","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib90","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0190-9622(99)80058-9","article-title":"Effects of acitretin on the liver","volume":"41","author":"Roenigk","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib91","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0190-9622(88)70167-X","article-title":"Effects of retinoids in bone","volume":"19","author":"Kilcoyne","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib92","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archderm.118.2.97","article-title":"Oral treatment of keratinizing disorders of skin and mucous membranes with etretinate. Comparative study of 113 patients","volume":"118","author":"Mahrle","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib93","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2133.1996.tb16226.x","article-title":"Topical retinoic acid changes the epidermal cell surface glycosylation pattern towards that of a mucosal epithelium","volume":"134","author":"Griffiths","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib94","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s004030050420","article-title":"The loss of desmosomes after retinoic acid treatment results in an apparent inhibition of HaCaT keratinocyte differentiation","volume":"291","author":"Wanner","year":"1999","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib95","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01973261","article-title":"Biological effects of cyclosporin A: a new antilymphocytic agent","volume":"6","author":"Borel","year":"1976","journal-title":"Agents Actions"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib96","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol Today"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib97","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/357695a0","article-title":"Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation","volume":"357","author":"Clipstone","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib98","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1523-1747.2002.01709.x","article-title":"Localization of calcineurin\/NFAT in human skin and psoriasis and inhibition of calcineurin\/NFAT activation in human keratinocytes by cyclosporin A","volume":"118","author":"Al-Daraji","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib99","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/1523-1747.ep12464387","article-title":"Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media","volume":"91","author":"Fisher","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib100","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJM197909063011015","article-title":"Cyclosporin A for psoriasis","volume":"301","author":"Mueller","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib101","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/bmj.293.6549.731","article-title":"Clearance of psoriasis with low dose cyclosporin","volume":"293","author":"Griffiths","year":"1986","journal-title":"Br Med J"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib102","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1001\/jama.256.22.3110","article-title":"Cyclosporine improves psoriasis in a double-blind study","volume":"256","author":"Ellis","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib103","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2133.1988.tb01772.x","article-title":"Low-dose cyclosporin A in severe psoriasis. A double-blind study","volume":"118","author":"Van Joost","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib104","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.0366-077X.2004.05949.x","article-title":"cyclosporine in psoriasis clinical practice: an international consensus statement","volume":"150","author":"Griffiths","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4400","article-title":"A systemic review of treatments for severe psoriasis","volume":"4","author":"Griffiths","year":"2000","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib106","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM199101313240501","article-title":"Cyclosporine for plaque-type psoriasis: results of a multi-dose, double-blind trial","volume":"324","author":"Ellis","year":"1991","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clindermatol.2007.11.006_bib107","volume":"187","year":"1993","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib108","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2133.1997.tb02135.x","article-title":"Treatment of psoriasis with intermittent short-course cyclosporin (Neoral). A multicentre study","volume":"136","author":"Berth-Jones","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib109","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2133.1999.02977.x","article-title":"Intermittent short courses of cyclosporin (Neoral\u00ae) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomised study","volume":"141","author":"Ho","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib110","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1067\/mjd.2001.112400","article-title":"Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study","volume":"44","author":"Ho","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib111","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00128071-200102010-00007","article-title":"Cyclosporine in severe psoriasis: results of a meta-analysis","volume":"2","author":"Faerber","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib112","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0190-9622(97)80219-8","article-title":"Cyclosporine as maintenance therapy in patients with severe psoriasis","volume":"36","author":"Shupack","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib113","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1365-2133.1998.02319.x","article-title":"A randomised, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis","volume":"139","author":"Koo","year":"1998","journal-title":"Br J Dermatol"},{"issue":"suppl","key":"10.1016\/j.clindermatol.2007.11.006_bib114","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2133.1990.tb02877.x","article-title":"Four years of experience with cyclosporin A for psoriasis","volume":"36","author":"Powles","year":"1990","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib115","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/0190-9622(95)91393-9","article-title":"Long-term maintenance therapy with cyclosporine and post-treatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study","volume":"33","author":"Mrowietz","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.1990.tb02875.x","article-title":"A consensus report: cyclosporin A therapy for psoriasis","volume":"122","author":"Mihatsch","year":"1990","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib117","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1056\/NEJM199206183262502","article-title":"Risk factors for cyclosporin-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporin in Autoimmune Diseases","volume":"326","author":"Feutren","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib118","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","article-title":"Risk of malignancies in psoriasis treated with cyclosporine: a 5-yr cohort study","volume":"120","author":"Paul","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib119","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-4362.36.s1.5.x","article-title":"Potential drug interactions with cyclosporine","volume":"36","author":"Katz","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2006.07343.x","article-title":"Update on the use of cyclosporine in immune-mediated dermatoses","volume":"155","author":"Griffiths","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2007.11.006_bib121","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1046\/j.1365-2230.2001.00870.x","article-title":"Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis","volume":"26","author":"Ameen","year":"2001","journal-title":"Clin Exp Dermatol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X07002660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X07002660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T13:50:22Z","timestamp":1709214622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X07002660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":121,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0738081X07002660"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2007.11.006","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}